An Open Label, Phase I Trial to Investigate the Pharmacokinetics and Pharmacodynamics of Linagliptin (BI 1356) 5 mg After Single and Multiple Oral Administration in Patients With Type 2 Diabetes Mellitus of African American Origin for 7 Days.
Phase of Trial: Phase I
Latest Information Update: 27 May 2014
At a glance
- Drugs Linagliptin (Primary)
- Indications Type 2 diabetes mellitus
- Focus Pharmacodynamics; Pharmacokinetics
- Sponsors Boehringer Ingelheim Pharmaceuticals
- 10 Jun 2017 Biomarkers information updated
- 14 Sep 2010 Actual end date (Aug 2010) added as reported by ClinicalTrials.gov.
- 14 Sep 2010 Status changed from recruiting to completed as reported by ClinicalTrials.gov.